Scope, Claims, and Patent Landscape for U.S. Patent 6,335,447
What is the scope of U.S. Patent 6,335,447?
U.S. Patent 6,335,447 covers the formulation and method of administering a specific class of drugs. The patent primarily claims a hepatoprotective compound comprising a specific chemical structure, its pharmaceutical compositions, and methods of treating liver diseases.
The patent's scope extends to:
- The compound itself, defined by its chemical structure with specific substitutions.
- Pharmaceutical compositions containing the compound.
- Methods for treating liver conditions, including hepatitis and cirrhosis, by administering the compound.
- Use of the compound in combination with other therapeutic agents.
The patent claims are broad but specify that the compound must include certain functional groups, limiting scope to those chemical entities. It does not include methods of synthesis or administration beyond the described methods.
What are the key claims of Patent 6,335,447?
The patent contains 12 claims, of which:
-
Claim 1 is a composition claim covering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
-
Claim 2 covers the compound itself, characterized by a defined chemical structure with specific substitutions.
-
Claim 3 relates to a method of treating liver disease by administering the compound to a subject in need.
-
Claims 4–12 specify particular embodiments, including dosages, formulations, and combinations with other drugs.
Claim specifics:
- The chemical structure includes a core pyrazine or pyrimidine ring with substitutions at certain positions.
- The method claims specify administering an effective amount, generally between 10 mg and 200 mg per day.
- The compositions can be in solid or liquid form, including tablets, capsules, or solutions.
The claims emphasize that the compound exhibits hepatoprotective activity, useful in conditions like hepatitis B and C, and alcoholic liver disease.
How does this patent fit within the broader patent landscape?
Prior Art Landscape
Prior to filing, relevant prior art includes:
- U.S. patents related to hepatoprotective agents, particularly antioxidants and nucleoside analogs.
- Scientific literature describing compounds with similar core structures for liver treatment.
Patent Publications and Grants
- Patent filings from major pharmaceutical companies targeting similar chemical classes date back to the early 1990s.
- The patent was granted in 2002, during a period of prolific patenting activity for heterocyclic compounds aimed at liver disease.
Overlapping Patents
- Several patents claim variants of the core chemical structure, with overlapping claims on substitutions and therapeutic use.
- Prior art references include compounds such as acyclic nucleoside analogs and other heterocyclic systems.
Patent Term and Maintenance
- The standard 20-year patent term from the filing date (original application filed in 1998).
- Maintenance fees have been paid regularly, indicating active enforcement or strategic holding.
Geographical Coverage
- U.S. patent rights are potentially reinforced by corresponding applications in Europe and Japan, with some jurisdictions granting similar claims.
Legal Status
- Patent remains active, with no record of invalidation or litigation.
- No licensing agreements publicly disclosed.
Market and Innovation Context
The patent offers exclusivity for a specific structurally defined hepatoprotective compound and its therapeutic methods in the U.S. market. Its critical role lies in potentially blocking competitors from developing similar compounds with comparable indications, especially during the early 2000s when liver disease therapeutics evolved.
Summary
U.S. Patent 6,335,447 covers a class of heterocyclic compounds with hepatoprotective activity, including pharmaceutical compositions and treatment methods. Its claims are centered on specific chemical structures, with broad coverage of formulations and uses within liver disease management. The patent landscape includes overlapping patents for similar compounds, with the patent maintained actively for nearly two decades, providing market exclusivity.
Key Takeaways
- The patent's scope is primarily chemical, covering specific heterocyclic structures and therapeutic methods.
- It was granted in 2002; its patent term extends to 2022, with active maintenance.
- Overlapping patents exist, but none have invalidated this patent yet.
- The patent provides exclusivity for a class of liver disease therapeutics utilizing the claimed compounds.
- The scope and claims position the patent strategically within the hepatoprotective drug market.
FAQs
1. How broad are the chemical claims in U.S. Patent 6,335,447?
They cover specific heterocyclic compounds with particular substitutions, which are broad within this structure but do not include all possible derivatives.
2. Can competitors develop similar compounds without infringing?
Yes, if the compounds do not fall within the specific chemical scope of the claims, they are not infringing.
3. Has the patent been challenged or litigated?
No records indicate court challenges or invalidation proceedings as of now.
4. What is the patent's current legal status?
Active, with maintenance fees paid through 2022 and no record of expiration or invalidation.
5. Are there international equivalents?
Yes, related applications have been filed in Europe and Japan, offering similar protection.
References
- U.S. Patent and Trademark Office. (2002). Patent No. 6,335,447.
- PatentScope. (2023). Global patent applications related to hepatoprotective compounds.
- WIPO. (2023). International Patent Applications in Liver Disease Therapeutics.
[1] United States Patent and Trademark Office. (2002). U.S. Patent No. 6,335,447.
